Sentinel lymph-node biopsy in early-stage cervical cancer: the 4-year follow-up results of the senticol 2 trial

Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study

SENTIX - Accuracy of preoperative local staging in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

Results of NSGO-OV-UMB1/ENGOT-OV30 study: A phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)

Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets

[VIRTUAL] STELLA-2 trial: Surgical complications comparing extraperitoneal vs transperitoneal MIS aortic staging in early stage ovarian and endometrial cancer

[VIRTUAL] Sensitivity and false negativity of SLN frozen section histological evaluation in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

[VIRTUAL] Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients

Dose modification for Chinese patients on niraparib maintenance treatment for platinum-sensitive recurrent ovarian cancer: A post hoc analysis

Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial

Efficacy and safety of maintenance olaparib by patient age in non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer in OPINION

The impact of intensive follow-up on health-related quality of life and costs in endometrial cancer patients: data from the TOTEM trial NCT00916708

Efficacy of niraparib by timing of Surgery and residual disease: Post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer